For decades, researchers have known there is a striking epidemiological link between infection with Epstein–Barr virus (EBV) and the later development of multiple sclerosis (MS). Almost everyone is exposed to the virus at some point in their lives, yet MS remains relatively rare — a mismatch that has long raised a fundamental question in neurology and immunology: how does a common viral infection translate into a highly specific autoimmune disease?
A newly published study in Cell offers new insight into that question, outlining a concrete immune mechanism through which EBV infection may directly contribute to MS-related neuroinflammation.
Led by researchers at Karolinska Institutet, the study identifies a population of EBV-activated CD4⁺ T cells that also recognise anoctamin-2 (ANO2), a protein expressed in the central nervous system and previously implicated in MS. In practical terms, the same immune cells primed to fight EBV are shown to cross-react with a self-antigen in the brain, creating a plausible biological bridge between viral exposure and autoimmune damage.
This type of “molecular mimicry” has been suspected in MS and other autoimmune conditions for years, but proving it convincingly in humans has been difficult. Immune responses are highly individual, relevant cells are often rare, and separating cause from coincidence has been a persistent challenge. The researchers describe their findings as the first mechanistic evidence demonstrating how EBV-specific T cells can directly target an MS-related autoantigen.
The implications are significant. EBV infects more than 90% of adults worldwide, yet only a small fraction develop MS. Understanding which immune responses cross the threshold into autoimmunity — and why — is essential if the field is to move beyond correlation studies and towards more targeted prevention strategies or early interventions.
A methodological contribution from industry
While the research itself is investigator-driven, the study also highlights the role of increasingly sophisticated immune-profiling tools in modern autoimmune research.
One of the techniques used to identify rare, antigen-specific T cells was developed by Neogap Therapeutics, a Swedish biotechnology company focused on personalised cancer immunotherapy. The company was not involved in the study’s disease focus or experimental design, but contributed a method that allowed researchers to detect and analyse highly specific T-cell responses central to the findings.
In this work, antigen-coupled particles were used to isolate T cells that reacted both to EBV and to ANO2. Such cells typically occur at very low frequencies in human samples and are difficult to characterise using conventional approaches, making their reliable detection a key technical hurdle.
The method originates from academic research led by Hans Grönlund — now Neogap’s chief scientific officer — who is listed as a senior author on the paper.
Why the findings matter beyond MS
Although the study is focused squarely on MS, its broader significance lies in how it reframes the EBV–autoimmunity relationship. Rather than acting as a vague risk factor, EBV is shown to drive a specific immune response capable of misfiring against the nervous system.
That clarity could influence how researchers think about prevention, including whether targeting EBV-related immune pathways — or even EBV infection itself — might reduce MS risk in susceptible individuals. It may also help explain why MS often emerges years after primary infection, as immune memory and cross-reactive T cells persist over time.
From a biotechnology perspective, the work also underscores how tools developed in one therapeutic area can inform another. Cancer and autoimmune diseases are both shaped by highly specific immune recognition events, and the ability to precisely identify those responses is increasingly central to drug discovery and translational research.
As MS researchers digest the implications of the EBV–ANO2 connection, the study is likely to become a key reference point in the field. Less dramatically, it also serves as a reminder that some of the most meaningful advances in biotech come not from headline-grabbing clinical updates, but from carefully executed basic science that finally makes a long-standing puzzle begin to fit together.